Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
IXQUF (IXQUF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: IXQUF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -5.09% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.03 | 52 Weeks Range 10.35 - 12.89 | Updated Date 05/3/2025 |
52 Weeks Range 10.35 - 12.89 | Updated Date 05/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -3.91% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 84650568 | Price to Sales(TTM) - |
Enterprise Value 84650568 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 1610376 |
Shares Outstanding - | Shares Floating 1610376 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
IXQUF
Company Overview
History and Background
IXQUF represents Ixico PLC, a company specializing in clinical trial solutions. Founded in 2004, it has grown through organic development and acquisitions, becoming a leader in its niche market.
Core Business Areas
- Clinical Trial Solutions: Ixico PLC provides services for clinical trials, including image data analysis, software solutions, and biomarker data.
Leadership and Structure
The leadership team consists of experienced executives in pharmaceuticals and technology. Organizational structure is focused on R&D, sales, and service delivery.
Top Products and Market Share
Key Offerings
- Assessa: Assessa is a neuroimaging solution for clinical trials, providing quantitative analysis of brain scans. The market share data is limited. Competitors are mainly imaging and data analysis companies that sell similar software, such as Invicro, Bioclinica and others that offer centralized imaging for clinical trials.
Market Dynamics
Industry Overview
The clinical trial solutions market is expanding, driven by increased R&D spending in pharmaceuticals and the need for more efficient trial designs and data collection.
Positioning
Ixico PLC is a mid-sized player within the clinical trial solutions market, with competitive advantages in specialized neuroimaging and biomarker data.
Total Addressable Market (TAM)
The clinical trial imaging market is projected to reach billions of dollars, and IXQUF is positioned to capture a segment of this market.
Upturn SWOT Analysis
Strengths
- Specialized expertise in neuroimaging
- Established relationships with pharmaceutical companies
- Proprietary technology solutions
Weaknesses
- Limited scale compared to larger competitors
- Dependence on specific therapeutic areas
- Geographic concentration
Opportunities
- Expanding market for clinical trials
- Increasing adoption of AI in drug development
- Partnerships with CROs and technology companies
Threats
- Competition from larger CROs
- Regulatory changes
- Technological disruption
Competitors and Market Share
Key Competitors
- IQV (IQV)
- PPD (Thermo Fisher Scientific, TMO)
- ICON (ICLR)
Competitive Landscape
IXQUF has an advantage in some niche areas but competes with larger players with a broader range of offerings.
Major Acquisitions
SynaptixBio
- Year: 2024
- Acquisition Price (USD millions): 21
- Strategic Rationale: Bolsters IXICO's offering in pediatric neurological diseases, expanding its reach in rare disease trials. Gives IXICO SynaptixBio's imaging biomarkers and artificial intelligence (AI) capabilities.
Growth Trajectory and Initiatives
Historical Growth: The company has demonstrated steady growth driven by contracts and expanding services. No specific financial data can be provided here.
Future Projections: Future projections depend on the overall expansion of clinical trial activity and the company's ability to capture market share.
Recent Initiatives: Recent initiatives include expanding AI capabilities and securing contracts with leading pharmaceutical companies.
Summary
Ixico PLC is a specialized player in the clinical trial market, particularly for neuroimaging. The company has been growing steadily, but faces competition from larger firms with broader service offerings. The SynaptixBio aquisition helps with expanding into AI and expands the addressable market. Investors should watch competitive dynamics and emerging trends.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, market reports, industry analysis
Disclaimers:
Data is for informational purposes only and not financial advice. Market share data is estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About IXQUF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-10-07 | CEO, CFO, COO & Director Mr. Noah Aptekar | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | Website https://www.ixacq.com |
Full time employees - | Website https://www.ixacq.com | ||
IX Acquisition Corp. does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on companies in technology, media and telecommunications, and information and communication technology industries, as well as companies operating in telecommunications infrastructure, internet and technology, and digital services sectors in Europe and other markets. The company was incorporated in 2021 and is based in London, United Kingdom. IX Acquisition Corp. is a subsidiary of IX Acquisition Sponsor LLC.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.